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Sjögren‘s syndrome (SS) is a systemic autoimmune disease that typically affects the salivary and 
lacrimal glands leading to dry eyes and dry mouth, but the patients may also have systemic 
involvement. Most patients with SS carry autoantibodies, most often to the Ro (SSA) and La (SSB) 
proteins. During pregnancy, these autoantibodies can pass over from affected mothers to the fetus, 
who is then at risk of developing a congenital heart block (CHB). There is a prominent gender bias in 
systemic autoimmunity overall, particularly in SS where the ratio of women to men is approximately 
14:1. While some genetic susceptibility factors for SS have been identified, much about the interplay 
between genetics, sex and the varying clinical presentation of this disease needs further study.  
 In order to identify genetic associations with SS, we performed targeted sequencing of 1853 
immune-related loci in over a thousand clinically well characterized SS patients and population 
controls. After subgrouping the patients by clinical manifestations, we identified three independent 
genetic signals in the HLA locus for Ro/La autoantibody positive SS, that were absent in the antibody 
negative group. The two top associations further indicated higher risk of severe manifestations, 
including purpura, major salivary gland swelling and lymphadenopathy. Our findings demonstrate that 
two distinct subgroups of patients with SS can be defined by the presence or absence of Ro/La 
antibodies and genetic markers. 
 We and others have identified genetic variants associated with SS and/or the partially 
overlapping disease systemic lupus erythematosus (SLE). The frequency of these variants is the same 
in women and men in the general population. However, as the vast majority of patients are women, 
the risk of developing SS or SLE is much higher if the carrier is female. Genetic variants may 
contribute to different phenotypes via differential gene regulation, so called expression quantitative 
trait loci (eQTL). We hypothesized that sex may influence the eQTL effects of SS/SLE-associated 
genetic variants differentially in women and men, and discovered several associated variants that had 
sex-specific effects on the expression of nearby genes in CD19+ B cells. We also specifically studied 
the SS/SLE-associated FAM167A-BLK locus on chromosome 8, since the associated variants in this 
locus have prominent eQTL effects on the unknown gene FAM167A. We found the gene to be 
evolutionarily conserved, with one additional family member, but no other homologies in the genome, 
and the proteins to have a high level of intrinsic disorder. The gene is expressed in B cells, and we 
further found high expression in the lung of both mice and humans. We named the FAM167 encoded 
proteins Disordered Autoimmunity 1 and 2 (DIORA1 and 2), and will continue our efforts to further 
characterize their function.  
 CHB affects 1-3% of anti-Ro/La autoantibody exposed pregnancies, with a recurrence rate of 
approximately 12-16%. The relatively low recurrence rate, despite persistent maternal autoantibodies, 
suggests fetal susceptibility factors are important. We performed a genome-wide association study in 
patients with CHB and controls. We found genetic associations with variants in the HLA region, 
KCNT2 on chromosome 1, and several suggestive signals. Most women with Ro/La autoantibodies 
have a steady state interferon activation, and to study the interferon in anti-Ro/La autoantibody 
positive pregnancy, we sampled anti-Ro/La positive mothers and their neonates at the time of birth, as 
well as healthy control mother-child pairs, and analyzed cellular profiles and cytokine- and gene 
expression. We found that anti-Ro/La exposed neonates had measurable type I and II interferon in 
plasma, and increased NK cell frequencies. Intracellular interferon detected by flow cytometry in 
neonatal NK and T cells indicates the neonates may produce the interferon, and we confirmed 
neonatal cell ability for interferon production in vitro.  Notably, the genes near the CHB-associated 
signals were enriched for interferon regulation, suggesting an interplay between interferon activation 
and fetal genetic susceptibility factors in the pathogenesis of CHB. 
 In summary, this thesis presents novel insight into genetic associations with SS and CHB, and 
begins to delineate how genetic susceptibility interacts with biological context such as sex or 
intrauterine exposure to maternal immune factors to lead to disease. The results will be important in 
clinical practice for personalized treatment and follow-up strategies, and as a basis for future therapy 
development.    
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Autoimmunity is an umbrella term for any disorder caused by the immune system actively 
attacking any system in the body, or failing to temper immune processes initiated by outside 
sources, often leading to tissue destruction and/or a persistent autoimmune disease state.  
With the emergence of biologics - potent targeted therapies based on inhibiting particular 
processes within the immune system - many autoimmune diseases have seen a drastic 
improvement in the variety and efficacy of the available treatment options.2 However, 
preventive or curative treatment has not been found for most of these diseases, so further 
study is still needed. 
1.1 PRIMARY SJÖGREN’S SYNDROME 
Primary Sjögren’s syndrome is a systemic autoimmune disease characteristically affecting 
exocrine glands, particularly the lacrimal and salivary glands, leading to dryness of mucosal 
surfaces, most prominently of the eyes and mouth. Secondary Sjögren’s syndrome can be 
diagnosed when an individual with an established autoimmune disease develops symptoms of 
Sjögren’s syndrome. No patients with secondary Sjögren’s syndrome have been included in 
the studies in this thesis, thus, only primary Sjögren’s syndrome will be discussed and 
referred to only as Sjögren’s syndrome hereafter.  
The incidence rate of Sjögren’s syndrome is around 3 per hundred thousand adults, 
and the prevalence around 0.05-0.1%.3 The majority of patients with Sjögren’s syndrome are 
females over 40 years old (males make up less than 7% of the patients).4-6 The most common 
symptoms are dryness of the eyes and mouth, but many will develop extraglandular 
manifestations such as Raynaud’s phenomenon or purpura. A systemic activation of 
interferon responses is also a common manifestation, with more than two thirds of patients 
showing signs of interferon activity.7,8 Anti-nuclear antibodies, anti-Ro/SSA and/or anti-
La/SSB autoantibodies are present in the majority of the patients, as well as other 
autoantibodies such as rheumatoid factor. Sjögren’s syndrome autoantibodies will be 
discussed in more detail below. The presence of the anti-Ro/SSA and/or anti-La/SSB 
(hereafter referred to as anti-Ro/La) autoantibodies also confers a risk of neonatal lupus 
syndrome developing in children born to autoantibody positive mothers, also discussed in 
more detail below.  
Patients with Sjögren’s syndrome have an increased mortality due to an increased risk 
of lymphoma,9,10,11 and for a subset of patients, their Sjögren’s syndrome diagnosis can even 
be concomitant with a lymphoma diagnosis, particularly in men.12 These lymphomas are 
most often, but not exclusively, diffuse B cell lymphomas or marginal zone lymphomas,13 but 
an additional risk of non-Hodgkin’s lymphoma comes with germinal-center like structures in 
infiltrated minor salivary glands.14  
Great strides have been taken in the treatment of many autoimmune diseases since the 
turn of the last century. However, several clinical trials of varied sizes have tested the safety 
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and efficacy of various biological treatments for Sjögren’s syndrome, but most have failed to 
meet their primary endpoints (reviewed in:15). These trials included tests of Abatacept,16 and 
Rituximab (anti-CD20 treatment to deplete B cells) which showed moderate improvement of 
clinical outcomes in early trials,17,18 but was found to not be sufficiently effective in later 
trials.19 B-cell activating factor (BAFF) or BAFF receptor blockade (belimumab or 
ianalumab, respectively), also had a promising start,20,21 but still no breakthrough in later 
trials.22 The lack of success seen in some of these trials revealed a need for patient 
stratification before inclusion in clinical trials, and more studies on disease sub-phenotypes 
for Sjögren’s syndrome.   
There is a consensus in the field that some differentiation between patient subgroups 
is necessary. In 2015, Seror et al.23 found that there was a subgroup of patients, identified as 
having a prominent systemic type I interferon activation, which responded better to 
belimumab than their interferon-negative counterparts. More recently, age at onset has been 
suggested as a useful marker for distinguishing subgroups of Sjögren’s syndrome patients 
more likely to have more severe forms of disease.24 These studies match others stating several 
factors as potential defining features for subgrouping patients with Sjögren’s syndrome. In 
fact, a great number of parameters can vary from one patient to another and several methods 
have been tested to find the most relevant grouping variables, including the use of artificial 
neural networks.25 Below, I will discuss some of the prominent features of Sjögren’s 
syndrome and related diseases in more detail.  
1.1.1 Autoantibodies  
It is common for patients diagnosed with Sjögren’s syndrome to carry autoantibodies. The 
characteristic autoantibodies found in patients with Sjögren’s syndrome are the anti-Sjögren’s 
syndrome-related antigen A or B (anti-SSA/Ro or anti-SSB/La) autoantibodies targeting 
Ro52 (TRIM21), Ro60 (TROVE2) or La (SSB). These autoantibodies can be present up to two 
decades before diagnosis of Sjögren’s syndrome,26 and around 75% of patients with 
Sjögren’s syndrome are anti-Ro positive.27 Anti-Ro autoantibodies are also included in the 
most recent classification criteria for Sjögren’s syndrome by the 2016 American College of 
Rheumatology and European League Against Rheumatism,28 making these antibodies a 
defining feature of Sjögren’s syndrome and an important diagnostic marker.  
The Ro/La autoantibodies can be found in combination with each other, other 
autoantibodies (most notably other anti-nuclear-antibodies, ANAs), or solitary. Looking at 
only the anti-Ro positive, reports have showed isolated anti-Ro52 as being the most common 
(43% in: 29), and the same report found a third of anti-Ro/La carriers had both anti-Ro52 and 
anti-Ro60 autoantibodies, and a quarter was found to carry anti-Ro60 only. They also found 
that anti-Ro52 and Ro60 double-positivity correlated with Sjögren’s syndrome diagnosis, 
while isolated Ro52 or Ro60 correlated better with other autoimmune diagnosis. While anti-
La autoantibodies are most common in carriers of anti-Ro, a fraction of patients can be found 
to carry only anti-La. The phenotype of isolated anti-La, however, is a matter of some debate. 
Clinical features of isolated anti-La individuals have been suggested to not differ significantly 
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from antibody-negative individuals,30 but systemic associations with isolated anti-La have 
also been described.31 Overall, Sjögren’s syndrome patients carrying anti-Ro and/or La 
autoantibodies are more likely to have lymphocytic infiltrations of affected glands, systemic 
manifestations, B cell expansion and risk of lymphoma than their anti-Ro/La negative 
counterparts.5,32,33 
In the absence of anti-Ro/La autoantibodies, several alternatives have been suggested as 
prognostic markers for Sjögren’s syndrome, including ANAs, rheumatoid factor (RF) and 
anti-α-fodrin antibodies.34 Most of the different autoantibodies associate with different 
clinical presentations of Sjögren’s syndrome.35 ANAs without anti-Ro/La have been found to 
correlate specifically with primary biliary cirrhosis in Sjögren’s syndrome patients, and in 
combination with anti-Ro specifically with polyneuropathy,36 but co-occurrence of ANA and 
anti-Ro/La is a common feature in Sjögren’s syndrome. Cryoglobulins - immunoglobulins 
that precipitate at temperatures below 37°C - have been proposed as a prognostic marker for 
overall mortality9 and lymphoma development,37 specifically cryoglobulinemic vasculitis38 in 
patients with Sjögren’s syndrome. Anti-centromere antibodies (ACAs) rarely overlap with 
anti-Ro/La, but have been suggested to define a distinct subgroup bordering both limited 
scleroderma and Sjögren’s syndrome with a different disease course but high risk of non-
Hodgkin’s lymphoma.39,40 Patients with dry eyes or mouth who have 
hypergammaglobulinemia without enough other diagnostic markers to get a diagnosis of 
Sjögren’s syndrome are more likely to progress towards a diagnosis in a couple of years than 
those who lack both hypergammaglobulinemia and hypocomplement.41 So overall, not only 
the presence of particular autoantibodies but also hypergammaglobulinemia (increased levels 
of polyclonal gamma immunoglobulins (IgG)) can also be a marker for increased risk of 
Sjögren’s syndrome. 
1.1.2 Genetics  
Over the course of the last two decades, genetics have been shown to be an important risk 
factor for the development of autoimmunity. Having a first degree relative with Sjögren’s 
syndrome makes one more likely to develop Sjögren’s syndrome, or another autoimmune 
disease,42 so there is a clear genetic component to disease susceptibility. Several studies have 
found associations between genetic variants, particularly variation in the HLA locus on 
chromosome 6, with an overall risk for Sjögren’s syndrome development. Below, I will 
broadly summarize the main findings made in this field so far.  
The result of the first genome-wide association study of Sjögren’s syndrome in 
Caucasians was published in 2013,43 which confirmed previously identified genetic 
associations, mainly with the HLA region, and revealed new associations. The loci/regions 
most significantly associated, after HLA, were the IRF5-TNPO3, STAT4, IL-12A, FAM167A-




Associations with IRF5 and STAT444, BLK-FAM167A, TNFSF4 and EBF1,45 had 
previously been published in candidate-gene studies in the Scandinavian population, and a 
candidate-gene study published at a similar time in 2013 confirmed the association with 
TNIP1 variants in Scandinavians,46 particularly in anti-Ro positive patients. Many of these 
associations have been replicated in samples from patients of other ethnicities,47,48 and several 
associations have been identified since (reviewed in: 49,50). Among them, GTF2I has been 
found to be associated with Sjögren’s syndrome in Han Chinese but not Caucasians,48,51,52 
and contradicting findings have been made in regards to associations with TNFAIP3.53,54 
Overall, there is a heterogeneity in both the clinical presentation and the genetic associations 
found with Sjögren’s syndrome depending on ancestry,55 and studies on more detailed 
subgroup analysis might yield new insight into disease pathogenesis.  
Like HLA, STAT4 and IRF5, the BLK-FAM167A locus on chromosome 8 has been 
associated with other autoimmune diseases, including: rheumatoid arthritis 56, systemic lupus 
erythematosus,57 systemic sclerosis,58 dermatomyositis,59 primary antiphospholipid 
syndrome,60 and finally Kawasaki disease, where the association with the BLK-FAM167A 
locus was the most significant finding.61 However, when looking into expression quantitative 
trait loci or eQTL effects of the associated variants, the BLK-FAM167A locus stands out, 
because of the prominent effect of the associated genotype on the expression of FAM167A in 
B cells.62 The Family with sequence similarity 167 or FAM167 gene family contains two 
members; FAM167A (C8orf13) on chromosome 8p23.1 and FAM167B (C1orf90) on 
chromosome 1p35.1. The genes have been grouped by shared sequence similarity but share 
no homology to other known genes or domains, so what role FAM167A might play in the 
pathogenesis of autoimmune diseases is unknown.  
The associations mentioned above vary in their distribution and effects, and much is yet 
to be discovered in this field, but the strongest genetic association in studies on any 
population of Sjögren’s syndrome patients tested so far remain with variants in the HLA 
region. For decades, we have been aware of an association between Sjögren’s syndrome and 
HLA variants.63,64 In a meta-analysis covering 1166 cases with Sjögren’s syndrome and 6470 
controls published in 2012, the association with HLA class II genes was mapped to 
DQA1*0501, DQB1*0201 and DRB1*0301,65 a finding confirmed by Lessard et al., in 
2013,43 well establishing that particular HLA alleles confer a risk of developing Sjögren’s 
syndrome.  
In addition to genetic variation, recent evidence has also pointed towards a role for 
epigenetic regulation in disease pathogenesis. Numerous Sjögren’s syndrome associated 
genetic variants have been shown to have methylation quantitative trait loci (meQTLs).66-68 
Interestingly, interferon regulated genes are hypomethylated in whole-blood, B cells and 
minor salivary gland biopsies from patients with primary Sjögren’s syndrome,69 supporting a 
role for epigenetics in the induction and/or maintenance of interferon responses found to be 
aberrant in patients with Sjögren’s syndrome (discussed further below). Epigenetics and 
genetic associations with Sjögren’s syndrome are reviewed in:50.  
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1.1.3 Sex  
Males make up less than a tenth of all Sjögren’s syndrome patients, yet male sex is a risk 
factor for increased mortality and/or more severe systemic disease.9,70,71 We know that being 
female confers a greater risk of developing autoantibodies and autoimmune disorders such as 
Sjögren’s syndrome, but we don’t know why. 
The female to male ratio in 
Sjögren’s syndrome is not a static 
variable, but one very dependent on 
geolocation,27 ranging from as low as 7:1 
in black/African-American populations, 
to 27:1 in Asian patients (Figure 1). The 
same can be said for the frequency of 
associated genetic variants, which can 
differ drastically between populations,55,72 
as well as the clinical presentation of the 
disease,73 so filtering out the signal from 
the noise in the hunt for risk factors for 
Sjögren’s syndrome can prove difficult. 
However, given the amount of time, 
money and effort that has been spent on 
defining both genetic and environmental 
risk factors for sex-influenced autoimmune disorders, the influence of sex remains 
remarkably understudied.  
Sex hormones have long been suspected to drive the sexual dimorphism seen in 
many autoimmune disease, and with good reason. Examples of systemic lupus erythematosus 
onset after male to female gender reassignment suggest a direct connection with sex 
hormones,74 and the onset of diseases like Sjögren’s syndrome being concomitant with drops 
in both estrogen, as well as androstenedione and testosterone levels in women after 
menopause75 make a compelling argument for a role for sex hormones in disease 
development, however, the presence of autoantibodies decades before disease onset would 
suggest that additional risk factors are needed. One of the proposed mechanisms for sex 
hormone influence on autoimmunity is androgen-induced immunosuppression (reviewed in: 
76). Androgen receptors are widely expressed, and variations in androgen levels have been 
associated with fluctuations in immune function.77 Estrogens can also modify the potency of 
immune responses in a myriad of ways, including upregulating immunoglobulin production, 
downregulating B lymphopoiesis,78 and altering the galactosylation79 and sialylation of 
autoantibodies.80 A direct role for sex hormones in the pathogenesis of Sjögren’s syndrome 
was suggested by Ainola et al. in 2018,81 when they found that androgens protected epithelial 
cells from apoptosis and induction of Sjögren’s syndrome autoantigens as well as affecting 
Toll like receptor 7 and 9 expression. However, using sex hormones as a form of treatment, 
for example with androgen treatment to ameliorate autoimmunity, have for the most part not 
Figure 1: Comparison of sex as a risk factor for primary 
Sjögren’s syndrome compared to examples of other risk factor 




proven successful (reviewed in: 82), but targeting other members of androgen signaling 
pathways or utilizing the immunological effects of androgens in other ways warrants further 
study.  
Outside the realm of sex-hormones and environmental factors, genetic factors can be 
a potent modulator of sex-differences in autoimmunity. Carriers of two X chromosomes 
(females and individuals with Klinefelter syndrome) tend to have more susceptibility to 
developing systemic autoimmunity and autoimmune diseases with more female-
predominance,83,84 while carriers of only one X chromosome (males and individuals with 
Turner syndrome) have a higher risk of other autoimmune disorders with more male 
dominance,85 (reviewed in: 86). Also, trisomy of the X chromosome (47, XXX) was found in 
excess among Sjögren’s syndrome patients and systemic lupus erythematosus patients.87 Rare 
X chromosome abnormalities such as triple mosaicism or triplications of one arm of the X 
chromosome have also been shown to be present among Sjögren’s syndrome patients,88 so a 
certain amount of risk appears tied to X chromosome numbers.  
There are several ways in which X chromosome counts could have this effect, and 
one of them is genetic variations on the X chromosome. The X chromosome is home to many 
important immune genes, such as Toll-like receptors, CD40 ligand, FOXP3 and IL-2RG to 
name a few. Genetic studies have revealed disease associations with X chromosome loci, 
including variants near Toll-like receptor 7 and others.89,90 On the other hand, studies tying X-
linked susceptibility genes and clinical features of systemic lupus erythematosus have only 
found moderate effects,91 so there is more work ahead before these effects can be fully 
understood.    
Epigenetic regulation and ineffective X-chromosome inactivation are also potential 
candidate causal manifestations of X chromosome dosage. XIST, a gene inside the X 
inactivation center that is essential for the initiation and spread of X-inactivation, along with 
some of its regulators, has been found to be overexpressed in the affected salivary glands of 
patients with Sjögren’s syndrome.92 The same study also found several X chromosome genes 
to apparently escape X inactivation specifically in tissues from patients with Sjögren’s 
syndrome.  
As most genetic risk factors will usually disseminate from carriers to female and 
male offspring in equal measure, the reasons for the increased incidence in females is 
unlikely to stem from disproportionate counts of risk alleles (outside the sex chromosomes), 
but rather sex-specific downstream effects. Males are overall less susceptible to both 
Sjögren’s syndrome and systemic lupus erythematosus, but they have also been reported to 
suffer from a more severe form of the disease.93 This could partly stem from milder cases 
being under-diagnosed in males, but is unlikely to explain the large difference in frequency 
observed between the sexes. A difference in the threshold for developing these diseases has 
also been suggested. Then, males with Sjögren’s syndrome or systemic lupus erythematosus 
would need to accumulate a greater number of risk factors to progress to autoimmune 
disease, but disease severity would be higher due to this risk factor accumulation. In fact, 
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looking at families of males diagnosed with systemic lupus erythematosus showed increased 
prevalence of more severe renal disease in affected female relatives who supposedly had 
similar risk exposures,94 supporting the theory that in high risk families with an accumulation 
of genetic and even environmental factors, more males would pass the threshold and develop 
disease. This has been further evidenced in systemic lupus erythematosus studies using 
genetic risk score aggregation methods, where sex has an opposite effect in highly affected 
patients compared to other patients (seen for the ‘renal’ subset compared to the less affected 
‘SLE’ subsets in: 95), and men overall require a higher number of risk alleles to develop 
disease.96  
The factors mentioned above are not mutually exclusive, and likely function in 
parallel to some extent. One possibility is an interplay between genetic variants and sex-
specific factors like hormones. Sex hormones like estrogen can drastically influence gene 
expression by signaling through receptors that are expressed in a wide variety of cell types, 
including immune cells (reviewed in: 97). Estrogen receptors also function as transcription 
factors to regulate transcription, so differences in estrogen receptor signaling could impact 
how genetic polymorphisms could influence disease. Be it directly through such a 
mechanism, or via any environmental or other sex specific influence, genetic risk variants 
might elicit a sex-specific response on gene-expression, generating so called sex-expression 
quantitative trait loci (sex-eQTLs).  
In summary, there is a known sexual dimorphism in most autoimmune diseases, 
particularly prominent in systemic autoimmunity. This dimorphism might stem from a 
variety of factors, alone, or more likely in combination including: Sex hormones, 
environmental factors, and genetics (Figure 2). This field of study has gained much needed 
momentum in recent years, but the intricacies of how, when, where, and why our sex dictates 
the way our immune systems react to stimuli remains unclear. 
 
Figure 2: Summary of potential influences on sexual dimorphism in autoimmunity 
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1.1.4 Interferons  
Interferons are a family of virus response proteins released by the host to fend off a virus 
infection. There are three families of interferons - type: I, II and III, each with different 
characteristics and binding to different receptors (Figure 3). The type I interferons include: 
interferon α, which in humans is encoded by 13 different IFNA genes, β (encoded by IFNB), 
interferon ε (IFNE), interferon κ (IFNK) and interferon ω (IFNW), and all binding the 
IFNAR1 and IFNAR2 encoded type I interferon receptor. The only type II interferon is 
interferon γ (IFNG). The type III interferons are the different interferon λ (IFNL), the last to 
be discovered and least known of the three.98 The large range of different type I interferons 
makes it difficult to measure their levels directly, however, signaling through the type I 
interferon receptor leads to a signaling cascade that results in the expression of a many 
interferon-response genes and their expression is generally easier to assess as a proxy for type 
I interferon activity.99 Under normal circumstances, type I and III interferons are necessary 
for protective immunity against viruses, and type II interferons for anti-mycobacterial 
responses (reviewed in: 100), but dysregulation of all families of interferons has been seen in 
patients with autoimmune diseases.101 
 
Figure 3: Schematic view of the three interferon family receptors for type I, type II and type III interferons, modified from.102 
Interferons are viral response proteins upregulated in patients with systemic 
autoimmunity, but the reason for this upregulation is not fully understood. Monogenic 
interferonopathies hint at an explanation. Aicardi-Goutièrs syndrome is caused by mutations 
in the Three-Prime Repair Exonuclease 1 (TREX1) or ribonuclease H2 genes103 (RNASEH2A, 
RNASEH2B, RNASEH2C) which lead to an accumulation of nucleic acids, an induction of 
type I interferons and inflammation (reviewed in: 104,105). In such cases, mutations in single 
genes can cause an induction of interferon responses and a phenotype that in some ways 
resembles systemic lupus erythematosus. That shows that interferons can be induced without 
viruses, and cause inflammation and autoimmune-like symptoms on their own. 
Patients with Sjögren’s syndrome often have systemic activation of interferon 
production and interferon responses.106 In patients with Sjögren’s syndrome, B cells have 
been shown to express prominent type I and type II interferon signatures,107 plasmacytoid 
dendritic cells - the main type I interferon producing cells - are activated to produce higher 
levels of type I interferons compared to cells from healthy controls108 and minor salivary 
 
 9 
gland tissue has been shown to express type III interferons109. Signs of activation of type I 
and II interferons have been found in 50-60% of patients with Sjögren’s syndrome,7,8,110 and 
coincide with an overall more affected phenotype. The effect of the apparent type III 
interferon activation in Sjögren’s syndrome or systemic lupus erythematosus is still being 
studied.101,111 The varied influence interferons might have in the pathogenesis of Sjögren’s 
syndrome was recently reviewed by Bodewes et al.112 and recent updates specifically in.102    
1.2 CONGENITAL HEART BLOCK 
Anti-Ro or anti-La autoantibodies are associated with Sjögren’s syndrome and impart an 
increased risk of both lymphoma and cardiovascular disease.113 However, these 
autoantibodies can also cause a passively acquired autoimmunity, the neonatal lupus 
syndrome, in fetuses exposed to maternal autoantibodies in utero. The neonatal lupus 
syndrome can present as a photosensitive rash, elevated liver enzymes or cytopenia in a 
neonate or infant, which clear once the autoantibodies are no longer present, and as a 
complete, permanent atrioventricular (AV) block. If the complete AV block develops, the 
mortality is high, with internationally reported figures of conservatively treated cohorts 
around 20-30%.114-116 Most fatalities occur in utero or during the first year of life. Those who 
survive often need a pacemaker soon after birth or in their first few months. Affected 
neonates are also smaller at birth,117 and more likely to develop attention deficits and other 
neurodevelopmental impairments later in life,118 so further study, and particularly finding 
preventive treatment might improve patient quality of life, in addition to reducing the 
mortality rate.  
Like other antibodies, anti-Ro/La autoantibodies are passively transferred 
across the placenta after the first trimester where their presence is associated with 
inflammation, fibrosis and a loss of conduction through the AV node.119 This only happens in 
1-2% of exposed individuals,120 and the recurrence rate in subsequent pregnancies is only 12-
16%.121-123  
So far, there is no preventive treatment for congenital heart block, however, early 
treatment with fluorinated steroids may have promise as a treatment for those who are 
affected.123,124 Hydroxychloroquine treatment is commonly prescribed to patients with 
Sjögren’s syndrome or systemic lupus erythematosus, and its use during pregnancy has been 
suggested to reduce the risk of congenital heart block,125,126 however, in order to treat and 
prevent congenital heart block, the central issue is identification of which individuals are at 
risk.  
1.2.1 CHB genetics  
The low recurrence rate of congenital heart block suggests that factors other than maternal 
autoantibodies might increase the risk of an AV block forming in an exposed fetus. While 
factors such as the levels of maternal autoantibodies,127,128 season of birth, and maternal age 
have been suggested,121,129 fetal risk factors emerge as likely candidates. As the autoimmune 
 
10 
AV block develops in utero, the most likely fetal risk factors would be genetically driven. 
The main findings of genetic associations thus far will briefly be outlined below.  
The most prominent genetic associations identified, and first to be discovered, have 
been with variants in the HLA locus. In 2010, genetic associations with variants in the HLA 
region and any cardiac manifestations of neonatal lupus were published, indicating regions 
near MICB as the most significantly associated.130 The same study found several suggestive 
associations outside the HLA, but none passed the genome-wide significant cutoff. Using 
family based approaches, associations with both class I and class II HLA alleles have also 
been described, including HLA-Cw*06, HLA-DQB1*06 and HLA-DRB1*13.131-133 Due to 
the rarity of the disease, genetic studies on a larger scale are practically difficult, but might 
prove necessary to identify additional variants that confer fetal genetic susceptibility.  
1.2.2 CHB and interferons   
Individuals with systemic autoimmune diseases can show signs of systemic interferon 
activity. Sera containing anti-Ro autoantibodies can induce type I interferon production by 
PBMCs in cell culture,134 and signs of a correlation between the interferon activity and a risk 
for developing neonatal lupus have been suggested after children born to autoantibody-
negative mothers receiving alpha-interferon therapy have developed neonatal lupus.135 Much 
like the fetuses exposed to autoantibodies and interferons due to maternal autoimmunity, only 
a fraction of fetuses exposed to interferon treatment in utero develop neonatal lupus, 
however, while the interferons alone might not induce congenital heart block in all exposed 
individuals, they likely contribute to disease pathogenesis in susceptible individuals.  
Several studies have since supported a relationship between interferons and the pathogenesis 
of congenital heart block risk. Studies have shown that mothers of children affected by 
congenital heart block have higher levels of type I interferons than mothers of unaffected 
children.136 The mothers also had increased expression of SIGLEC1, a suggested biomarker 
for interferon an autoimmune activity.8 Both SIGLEC1 and type I interferons have been 
found in samples of affected cardiac material137 and interferons have been suggested to affect 
fetal fibroblasts to facilitate tissue injury.138 Lastly, using single-cell RNA sequencing of a 
congenital heart block affected fetal heart, most cells were shown to upregulate interferon 
response-genes compared to healthy controls.139 However, much remains to be understood 






2 RESEARCH AIMS 
The aims for the projects in this thesis were to identify associations and interplay between 
genetic and biological factors that might influence susceptibility to, or the disease progression 
of, systemic autoimmune diseases, with a focus on Sjögren’s syndrome and its comorbidities. 
This included the study of factors such as autoantibodies and sex, and their relationship with 
genetic susceptibility factors for systemic autoimmune disease, and the elucidation of 
potential functional consequences of these associations. Moreover, examination of systemic 
autoimmunity in the context of pregnancy and the detrimental effects of maternal 
autoimmunity on fetal immune activation, with a specific focus on autoimmune congenital 
heart block were part of the studies.  
2.1.1 Specific aims 
- To identify genetic associations with Sjögren’s syndrome, and to identify potential 
subgroups of patients and means to distinguish them in terms of genetic variation and 
potential biomarkers (paper I). 
- To elucidate the interplay between sex and genetic polymorphisms relevant for the 
expression of genes in loci associated with autoimmune disease, to identify genes that are 
regulated in a sex- and disease-specific manner (paper II). 
- To elucidate the function and potential role of the novel autoimmune associated gene, 
FAM167A/DIORA1 in Sjögren’s syndrome (paper III).  
- To identify novel genetic associations with autoimmune congenital heart block (paper IV). 
- To elucidate the effects of maternal autoimmunity, particularly autoantibodies, on immune 
activation in neonates in utero, focusing on interferons and their downstream effects (papers 




3 MATERIALS AND METHODS 
In this chapter, some of the methodologies chosen for projects described in this thesis will be 
briefly discussed. Detailed listings of all the methods used for each project can be found in 
the attached papers and manuscripts.   
3.1 PATIENTS AND CONTROLS  
To identify and study different subgroups of Sjögren’s syndrome patients, we collected a 
large cohort of patients from Sweden and Norway and generated a detailed database of 
clinical information and coupled it with large scale targeted sequencing. The main advantage 
of this was providing the unique ability to couple distinct clinical manifestations with genetic 
polymorphisms on a much bigger scale than what had been done before. In this study, the 
patient cohort was coupled with population controls from both Sweden and Norway, 
including both blood donors and other population controls. The downside to this arrangement 
is that the controls are not matched specifically for age and region of origin, however, 
bioinformatics methods were used to quality control the patient and control cohorts and 
remove any outlying or related individuals from the study (paper I, supplementary figure S1). 
The specific quality control steps used are detailed in the attached supplementary (paper I, 
supplementary material, Methods). 
We collected clinical information related to the Sjögren’s syndrome diagnosis for all 
the included patients. This included variables such as age at disease onset, age at diagnosis, 
presence of various autoantibodies, extraglandular manifestations and lymphoma. This 
information had been collected center by center during the course of the diagnostic and/or 
treatment process for each patient and not systematically measured or collected for the sole 
purpose of the study. Therefore, variables of interest such as cryoglobulins or levels separate 
anti-Ro52 and anti-Ro60 were too poorly covered in our dataset to be of use. This manner of 
data collection also means that a particular subtype of patient might be more represented with 
clinical information, namely the patients missing the prototypic anti-Ro/La autoantibodies. 
To meet classification criteria in the absence of these autoantibodies, patients would have to 
present with positive minor salivary gland biopsy to qualify for the Sjögren’s diagnosis, and 
thus, salivary gland biopsies are completely covered in this group. In light of that, we 
excluded poorly covered clinical variables in downstream analysis. The anti-Ro/La 
information was present for all the patients included. For the more severe phenotypes such as 
lymphoma and interstitial lung disease, data collection would automatically skew towards 
more coverage for the affected patients, with the unaffected ones being less likely to be 
registered unaffected but the affected ones noted specifically. Despite this, we opted to not 
include variables with proportionally high levels of missing data (with a cutoff of 50%), and 
variables such as interstitial nephritis could not be included in the study.  
3.2 GENETIC ANALYSIS 
To perform a genetic association study for Sjögren’s syndrome, using a targeted sequence 
capture array (the ‘Immuno-array’ described in: 140), we targeted 1853 genes selected based 
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on their known or indicated roles in immunological or autoimmune diseases. While this 
method is then limited to the targeted regions, this method provided much better coverage for 
those loci than other methods in large scale use at the time. While whole-genome sequencing 
would have been a better choice, it was not a feasible option at the time, however, this 
method allowed for a close examination of the selected regions in a large scale and high 
quality to examine associations between Sjögren’s syndrome and known or suspected loci 
with immunological or autoimmune function.   
The Immuno-array was designed to capture the coding exons, 5’ and 3’ UTRs, 
potential promoter regions, and splice sites, as well as nearby regions of mammalian 
conservation (see paper I, supplementary materials, for details), in regions with potential 
function in autoimmunity. This way, potential coding variants, as well as regulatory variants 
with particularly high impact near the previously associated loci could be identified for 
further study. While the upside of this arrangement was the added coverage, interpretation 
and quality control of the data has some interesting aspects. Targeted methods are, by 
definition, more likely than others to detect significant associations. Therefore, determining 
an appropriate cutoff for significance can be debated. We chose the Bonferroni corrected 
cutoff (with α of 0.05), p<8.7*10-7 (based on 57,768 independent variants tested). Since this 
cutoff is arguably strict, we also considered suggestively associated variants (p<1*10-5), 
hopefully minimizing the type II errors in the analysis. The data collected using the Immuno-
Array makes analysis of rare variants and their potential association with Sjögren’s syndrome 
possible, however, that analysis is not included in the present study, and will not be discussed 
here. 
The prevalence of congenital heart block is one in 23.000 in Sweden141, so even a 
cohort collected in a population-based manner will be of limited size. Therefore, we reached 
out to centers in Norway, Finland, Greece and Italy, and formed a large cohort of patients for 
genotyping and analysis. This allowed us to collect more patients to increase the power for a 
genome-wide association study, however, collecting patients from diverse geographical 
origins can cause issues. To circumvent this, we used principal component analysis to 
exclude patients who were outliers from the main patient group, and a genetic relationship 
matrix (GRM) to control for variation within the cohorts tested. The GRM was generated 
using GCTA (cnsgenomics.com/software/gcta142) and used as a covariate for a mixed-linear-
model association analysis. This way, we were able to find loci associated with congenital 
heart block at a genome-wide level, with minimal inflation of the p values.  
Families affected by congenital heart block have a moderate likelihood of containing 
more than one affected child. Traditional methods of case-control genetic association studies, 
using linear or logistic regression, therefore require a significant reduction in the already 
small cohort sizes, since related individuals must be removed prior such analysis. To 
circumvent this, mixed model approaches have been implemented in many studies where 
relatedness between samples can be expected, particularly in twin studies. Using a cohort of 
congenital heart block cases that included affected first degree relatives allowed us to boost 
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the size of our cohort considerably and subsequently to identify novel associations using 
mixed linear model association methods.  
Any genetic association study attempted for congenital heart block will be complicated 
by maternal autoimmunity and the associated genetic variation. Mothers carrying anti-Ro/La 
autoantibodies often carry genetic variants such as HLA risk alleles that predispose them to 
autoimmunity and by Mendelian law, half of their offspring will inherit some of their risk 
alleles. Comparing the affected children to healthy controls then poses the risk of detecting 
maternal autoimmune risk alleles that may or may not contribute to the risk of congenital 
heart block. One method used to circumvent this is the transmission disequilibrium test 
(TDT) that has been applied previously in this setting on affected individuals and their 
parents.131,133 One of the most important strengths of the TDT test is its robustness in samples 
from mixed populations, as it is not sensitive to differences in population structure, however, 
the TDT test requires heterozygosity in the parents to adequately detect transmission 
disequilibrium with serious implications in terms of statistical power. Therefore, while the 
TDT will account for maternal autoimmunity better than most other association tests, it will 
quickly reach its limit in terms of power to detect new associations. Thus, we selected the 
mixed linear model case-control association testing as a logical addition to previously 
published family association studies to detect new genetic associations with congenital heart 
block.  
3.3 EQTL ANALYSIS  
To look for sex influenced eQTL effects, we used the following linear model in R: 
lm(Expression ~ SNP + Sex + SNP*Sex), where “Expression” represents the Z score 
normalized expression of the gene tested and “SNP” represents the “0”, “1” or “2” coded 
genotype. Thus, we measure the influence of genotype, sex and potential interaction between 
genotype and sex on the expression of the gene in question. What is missing from this 
equation due to the lack of availability of that information, is age. For optimal results, the 
model should have included the effect of age on the expression of the genes in question. Also, 
a limiting factor for the variants tested for sex*SNP interaction eQTL effects was including 
only healthy controls, since the disease associated alleles are scarce in healthy controls due to 
their disease associations. This had the most notable impact in the HLA region on 
chromosome 6 where insufficient allele counts were available for testing. Ideally, testing for 
sex-influenced eQTLs for disease associated variants should be performed in both healthy 
controls and patient samples, and including more control variables such as age.  
3.4 ANALYSIS OF INTERFERON ACTIVITY  
To examine the influence of type I interferons in our study, we have utilized several methods. 
One of the most common ones, as mentioned in the introduction (Interferons), is to measure 
downstream activity of type I interferons by assessing the expression of interferon induced 
genes. This is done because of the wide range of type I interferons, mainly interferon-alpha, 
that can be difficult to collectively measure but signal through the same receptor. For this, we 
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calculate the so-called interferon score, by using a range of interferon induced genes (IFI44, 
IFIT1, IFIT3, IRF7, ISG15, LY6E, MX1, MX2, OAS1, OAS2, OASL, PLSCR1 and STAT1) 
and calculating the score for each individual included as follows (described in: 143):  
IFN scoresample= ∑





We have shown that this method is quite robust and can be measured in a number of 
different ways with a consistent result.144 However, to examine the release of interferon alpha 
from neonatal cells exposed to antibody-containing plasma, we employed the DELFIA 
method which has been previously described.145 Several methods of direct measurement of 
interferon alpha have been used in the literature, including modified ELISA methods and the 
SIMOA assay.146 We have extensive experience using the DELFIA method and deemed it 
was appropriate for this purpose.  
In order to assess if fetal cells were in fact capable of responding to maternal 
autoantibody containing plasma by releasing type I interferons, we cultured fetal PBMCs in 
the presence of autoantibody containing plasma and healthy control plasma (paper V, figure 
4) and used DELFIA method mentioned above for interferon-alpha detection. This method 
allowed us to show, for the first time, that fetal cells can and will respond to plasma 
containing anti-Ro/La by releasing interferon. While the induction of type I interferons by 
anti-Ro/La autoantibodies has been shown before (see,134 and others), we realize that this 
experimental setup does show a direct effect of the autoantibodies on type I interferon 
release, as other mediators in the plasma could hypothetically have the same effect, and to 
demonstrate a direct effect, the autoantibodies would have to be purified from the plasma 
before culture with the PBMCs. However, we could unequivocally show that the autoimmune 
plasma, containing autoantibodies known to induce type I interferons, could induce 
interferon-alpha production in fetal PBCMs, while plasma from healthy controls did not.  
3.5 ETHICAL CONSIDERATIONS 
When studying human disease, there are multifaceted ethical considerations that must be 
made. Where relevant, all the studies included in this thesis were approved by the relevant 
ethical committees, and ethical considerations have been taken into account for both planning 
and execution of each of the studies.  
Any study collecting information about an individual’s genetic and/or disease history 
must consider data security and secure information handling as a priority. Extensive steps 
have been taken to encrypt and protect the clinical data collected for all the cohort studies 
included in this thesis, and access to the data is strictly controlled. Informed consent was 
obtained for all participants. When studying human disease, there are numerous other 
considerations that need to be addressed.  
Autoimmune diseases often entail progressive tissue damage leading to loss of function 
of affected organs, pain and morbidity for the affected individuals. This holds particularly 
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true for the study of congenital heart block, where the loss of function of the affected organ - 
the atrioventricular node - increases morbidity and mortality for the affected individuals 
considerably. Taking steps to better understand the causes and drivers of disease pathogenesis 
in order to make diagnosis or treatment more efficient could potentially reduce the level of 
tissue damage and pain the patient is exposed to. The potential for improved treatment, 
diagnostics or even a cure for autoimmune diseases provide a potential payoff for any patient 
that greatly outweighs the relatively minor cost of donating information and material for a 
genetic study such as the genetic association studies included in this thesis.  
Aside from the increased risk of congenital heart block, little is known about the effects 
of maternal autoantibodies in anti-Ro/La exposed pregnancies (with or without congenital 
heart block). We invited any at-risk pregnant woman being treated in the greater Stockholm 
area to participate in our study. Participation was entirely optional, and participants provided 
their informed consent, noting that discontinuation in the study could happen any time 
without any effect on the clinical monitoring or care during pregnancy. Peripheral- and cord-
blood from mother-neonate pairs were collected at the time of delivery according to routine 
procedure, with minimal risk to the mother. As the neonatal sample was collected from cord 
blood post-partum, the neonate is not at any risk during the sample collection. Since ethical 
permits for the suggested studies are approved, the consensus is that these projects are worth 




4 RESULTS AND DISCUSSION 
4.1 GENETIC ASSOCIATIONS WITH SJÖGREN’S SYNDROME   
4.1.1 Targeted sequencing of autoimmune loci in Sjögren’s syndrome 
patients and controls  
While updated methods of genotyping have made larger and more detailed studies of 
genotype-phenotype associations possible in the last decade or so, much remains unknown 
about the disease pathogenesis and susceptibility of many autoimmune diseases such as 
Sjögren’s syndrome. Efforts have been made to collect large cohorts of patients to increase 
the power to detect disease-related polymorphisms, and all that available data has revealed a 
disease heterogeneity more pronounced than previously expected. To identify subgroups of 
Sjögren’s syndrome patients to use for further study, we used a large, well characterized 
cohort of Scandinavian patients with Sjögren’s syndrome and compared them with 
population controls. We analyzed both clinical and genetic data to identify subgroups based 
on clinical information, and examined their association with specific genetic markers and 
phenotypes (Paper I).  
Using a principal component analysis of the clinical information collected, we were 
able to identify clear subgrouping in the patient cohort with the most distinct variable 
associated with the first principal component being the presence or absence of the anti-Ro 
and/or La autoantibodies. We tested this grouping variable on the genetic data, and found that 
using only the patients carrying the anti-Ro/La autoantibodies and comparing them with 
controls gave more significant associations with genetic variation in the HLA region (p 
2.2*10-62) than using the whole cohort (HLA-DQA1 p 1.4*10-46), despite a loss of power by 
reducing the size of the cohort. This was true for all three independent signals within the HLA 
locus found to be associated. Looking at the anti-Ro/La negative subgroup and comparing 
them with healthy controls, we found no genetic association with variation in the HLA region, 
and overall no genetic variants passed the significance threshold.  
The association between HLA and anti-Ro/La positivity has been described before.147-
150 However, we were able to detect different sub-phenotypes of Sjögren’s syndrome 
associated with the different variants within the HLA region, with variants near HLA-DQA1 
(rs6933289) and HCP5/HLA-B (rs3099839) correlating positively with younger age at onset, 
lymphadenopathy, major salivary gland swelling, hypergammaglobulinemia, other 
autoantibodies and more. These findings correlate well with previous publications, where 
younger age at onset was associated with more autoantibodies and an overall worse 
prognosis.24 We also found that an independently associated variant near HLA-DRA (rs7197) 
was more specific for anti-Ro autoantibodies and leukopenia and not the other extra-
glandular manifestations or autoantibodies. This way, we could show that the specific 
phenotypes dictated by autoantibody-positivity have a genetic basis that should be 
distinguishable not only when autoantibodies can be detected but as early as birth. The 
predictive value of such genetic information remains to be understood, but knowledge of the 
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disease-associated genotypes - potentially used together with other biomarkers - opens for 
possibilities for preventive or early-stage treatment. 
In our study, we found that the presence of either anti-Ro or anti-La autoantibodies 
correlated with both clinical and genetic variation in Sjögren’s syndrome, however, there are 
varied opinions in the field about the benefits of grouping the autoantibodies together in this 
manner. This group encompasses three autoantibodies in varied combinations; anti-Ro52 and 
anti-Ro60 (collectively referred to as anti-Ro), or anti-La. Each of these autoantibodies, alone 
or in combination, have been associated with separate clinical manifestations,29,151 with the 
combination of all three being most common in Sjögren’s syndrome compared to other 
diagnosis,29 and isolated anti-La with a more limited phenotype.30,31 Single positivity for 
either anti-Ro52 or anti-Ro60 can have varied clinical presentations,152,153 however, the 
combination of the two, with or without anti-La, is much more common in patients with 
Sjögren’s syndrome than other or no diagnosis. This would suggest that measuring single 
positivities for these autoantibodies is important for diagnostic purposes and/or other 
autoimmune or connective diseases. However, within the context of established Sjögren’s 
syndrome, the presence of anti-Ro52/Ro60 with or without anti-La, compared to negativity 
for all three, will associate with a more severe disease phenotype.   
For a patient with symptoms characteristic of Sjögren’s syndrome, being correctly 
categorized into one of the subgroups discussed above will be important for monitoring of 
disease progression and appropriate assessment of the risk of severe and potentially life-
threatening manifestations. Ideally, those more likely to develop severe disease could receive 
targeted treatment, however, following a wave of failed clinical trials,15 good treatment 
options for patients with Sjögren’s syndrome remain few and far between (reviewed in: 154). 
Biologic treatment has proven successful for some of the most severe of extraglandular 
manifestations,155 however, the main symptoms of Sjögren’s syndrome - dryness of the eyes 
and mouth with debilitating fatigue - remain only topically treatable.156 The failure of the 
clinical trials is thought to be due to patient heterogeneity as well as a lack of measurable 
disease outcomes,157 although drug inefficacy for Sjögren's syndrome is certainly also an 
option. The association we found with anti-Ro/La autoantibodies in the presentation, 
progression and outcomes of Sjögren’s syndrome could be of great benefit for defining 
patient groups eligible for clinical trials.  
Outside the HLA locus, we also identified associations with variants near interferon 
regulatory factor 5 (IRF5), Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2) and 
Glutamic-oxaloacetic transaminase-1 (GOT1). The association with variants near IRF5 and 
Sjögren’s syndrome has been published previously,43,44 however, we found that the 
association with IRF5, like the association with HLA, were stronger when comparing only the 
anti-Ro autoantibody positive patients to controls compared to the full cohort of antibody-
positive and negative patients. The GOT1 and MAP2K2 loci however, did not improve when 
we removed the anti-Ro/La negative patients from the analysis, and MAP2K2 association did 
not pass the significance threshold in the sub-group analysis while the GOT1 association 
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merely weakened. We then attempted to replicate these findings in a smaller Scandinavian 
cohort, but only found associations with the HLA and IRF5. The replication was however 
based on much smaller material (using 177 patients and 7672 Swedish population controls) 
so it is possible that the lack of replication is due to a lack of power in this case, and larger 
cohort studies might shed light on these associations and their potential role in the disease in 
the future.   
In summary, we used a large cohort of Sjögren’s syndrome patients and population 
controls and collected detailed clinical and genetic information for genetic association 
studies. Using the clinical information collected, we found clear signs of distinct patient 
subgroups in our cohort, best identified by the presence or absence of anti-Ro/La 
autoantibodies. The identified subgroups differed in their clinical presentation, with anti-
Ro/La being linked to younger age at Sjögren’s syndrome onset and several extraglandular 
manifestations. Also, there were clear differences in the genetic associations with Sjögren’s 
syndrome in the two groups - with the antibody carriers more often associating with both 
variants in the HLA locus and IRF5, but the patients not positive for these autoantibodies not 
showing any significant associations. These findings have potential benefits for both 
diagnosis, management and hopefully clinical trials for Sjögren’s syndrome.   
4.1.2 Sexual dimorphism in the expression of genes associated with 
autoimmune disease risk  
Systemic autoimmune diseases such as Sjögren’s syndrome and systemic lupus 
erythematosus show a prominent sexual dimorphism in their frequency and severity. Genetic 
association studies have found polymorphic genetic loci to be associated with these diseases, 
however, most of the disease associated polymorphisms are found in both males and females 
in the population in equal measure. Exploring the hypothesis that such polymorphisms may 
however lead to different functional effects if carried by a man or a woman, we explored 
potential influences of sex on the expression of genes near polymorphisms associated with 
either disease; in essence analyzing interactions between disease-related genotype and sex on 
gene expression using sex-eQTL analysis. We found that in CD19+ B cells, seven loci had 
genes with differential expression in males versus females depending on the presence of a 
nearby risk genotype (paper II).  
 In a recently published study using the large amount of data collected in the 
Genotype-Tissue Expression (GTEx) project, the impact of sex on eQTL effects in different 
tissues was explored.158 One of their main findings was that, while widespread, sex-eQTLs 
are very tissue specific, with a fair percentage of the variant-gene pairs identified having an 
effect in only one of the 44 tissues tested. While we examined fairly homogenous sorted cells 
in our cohort, the GTEx sex-eQTLs are based on whole tissues. However, we were able to 
replicate a genotype*sex interaction for one of the sex-eQTLs identified in our analysis 
between PXK and rs60612015 in adipose tissue, using a proxy for rs6445975 (r2 0.647) 
(Table 1). A further three variant-gene pairs from the original list of variants were discovered 
to have eQTLs in the GTEx data that were only significant in one sex and not the other, while 
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not reaching significance for the genotype*sex interaction term (Table 1). Both CTSB and 
PXK also had significant sex-eQTLs detected in several tissues for variants outside the 
autoimmune associated loci (not shown), suggesting widespread influence of sex on the 
expression of those genes.  
Table 1: Replication of sex-eQTLs in GTEx 
  
Variant id 
(Original variant, R2) 
    Genotype*sex Females Males 
Gene Tissue P Slope P Slope P Slope 
rs2814955 
(rs11755393, 0.926) 
UHRF1BP1 Artery (Tibial) 3.9E-03 -0.127 3.8E-32 0.634 5.6E-31 0.774 
rs9296128 
(rs11755393, 1.0) 






0.040 -0.146 1.3E-09 -0.470 2.3E-05 -0.36 





0.083 0.111 9.2E-05 0.334 0.066 0.137 
rs6445975 PDHB Pancreas 0.11 -0.131 0.62 0.0424 2.7E-03 0.249 
rs429503 
rs2732552, 0.956) 
CD44 Nerve (Tibial) 0.36 0.0425 4.8E-04 0.179 0.054 0.0822 
 
The variant-gene pair detected in both our analysis and in the GTEx data, PXK and 
rs6445975 (or proxy rs9296128) showed downregulation of PXK expression in both sexes in 
GTEx. We also found that the genotype*sex had a negative β value in our analysis, however, 
in B cells, the expression of PXK was upregulated in female carriers of the risk allele while 
male expression levels were largely unaffected (Paper II, figure 2C). We included variants in 
the PXK region because of their association with systemic lupus erythematosus, but the 
3p14.3 locus has also been associated with a number of other diseases and phenotypes, 
including systemic scleroderma, rheumatoid arthritis, acute myeloid leukemia and various 
measurements such as platelet count, hematocrit, hemoglobin and serum IgG (GWAS 
catalog159). PXK (PX Domain containing Serine/Threonine Kinase like) is a gene found in 
most tissues, with an elusive function and no obvious disease causing features at first glance. 
The locus has been extensively studied in the context of its association with systemic lupus 
erythematosus, and the neighboring gene ABHD6 was found to be most profoundly affected 
by the disease associated variants.160 In addition to the sex-eQTL effects we detected in PXK, 
we also found cis-eQTL effects of the disease associated variants on yet another gene in the 
locus, DNASE1L3. However, the associated signal has been mapped to one exon of PXK, 
with a functional implication in B cell receptor internalization being affected in disease allele 
carriers,161 so variation in this locus appears to have a broad effect on gene expression in a 
sex-dependent and independent manner.  
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The FAM167A/BLK locus has been documented to have some of the most profound 
eQTL effects in the human genome with the most prominent effect of autoimmune-associated 
polymorphisms on FAM167A expression in B cells.62 This was clear in our cis-eQTL analysis 
where we detected eQTL effects on three genes in the region, FAM167A, BLK and FDFT1. 
In the GTEx sex-eQTL data, the slope of the male and female eQTLs in spleen tissues were 
1.24 and 1.64, respectively, showing the magnitude of the effect on FAM167A expression. 
However, in our sorted B cell data, there was no detectable sex-eQTL effect on FAM167A 
expression, but only on the neighboring CTSB. The GTEx data had detectable FAM167A sex-
eQTLs for both the disease associated variants and variants not currently known to associate 
with autoimmunity (rs2572418 in thyroid tissues), however, it’s possible that the difference 
seen there stems from a difference in cell types present in the tissues and not a direct sex-
eQTL,158 although that would not subtract from any potential biological effects. In the 
chromosome 8 locus, we found sex-eQTL effects on CTSB (Cathepsin B) expression with 
autoimmune associated variants (rs922483 and rs13277113). CTSB has gained interest 
recently due to its function as part of the entry machinery for the SARS-CoV-2 virus 
responsible for the COVID-19 epidemic, and a recent study concluded that CTSB would be 
an unlikely driver of sex differences in disease progression seen in the COVID-19 
pandemic.162 However, our findings would contradict that conclusion and the increased 
expression of this SARS-CoV-2 entry machinery protein only on male B cells could be of 
interest in that context. In the GTEx data, there was also an exonic CTSB variant (rs4839) that 
only upregulated CTSB expression in lung tissues from males and not females carrying the 
variant, this locus has not been associated with systemic autoimmune disease but indicates a 
wider influence of sex on CTSB expression and potential implications in COVID-19 
responses.  
Among the other loci we identified sex-eQTLs for, the most prominent effects were 
on SLC39A8 expression in the disease associated BANK1 locus in chr4q24, and CD74 in the 
TNIP1 locus in chr5q33.1. The disease associated variants tested had opposite effects on gene 
expression in females compared to males, with the least disease associated genotypes causing 
lower expression in females but higher in males compared to carriers of the non-risk alleles. 
SLC39A8 (Solute Carrier Family 39 Member 8) is a metal ion transporter with a plethora of 
functions via control of ion transport in various cells. The function of SLC39A8 in the 
immune system is bound to the secondary effects of the ions it transports, making it an 
important regulator of immune function primarily through zinc metabolism.163 Knocking out 
SLC39A8 leads to early embryonic lethality, and reduced expression of SLC39A8 is linked to 
a wide variety of traits (reviewed in: 164), so the implications for the reduced expression in 
females carrying the autoimmune risk allele could be widespread. CD74 is a chaperone 
important for MCH class II antigen processing and it has been implicated in the pathogenicity 
of several autoimmune diseases (reviewed in: 165). Reducing CD74 levels in mouse models of 
systemic lupus erythematosus ameliorates the inflammatory symptoms, particularly in the 
kidneys.166 Female B cells showed reduced levels of CD74 in risk allele carriers, but 
increased in males. In systemic lupus erythematosus, males are less likely to develop the 
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disease, but if they do, they are more likely to get nephritis and end stage renal disease than 
females,167 so a connection between the increased levels of CD74 in males and its connection 
to renal function in systemic autoimmunity might be worthy of more study.  
Archain 1 (ARCN1) in the 11q23.3 locus neighboring CXCR5, was upregulated in 
female and downregulated in male B cells carrying the autoimmune risk genotype. Loss of 
function mutations in this gene, which encodes a coatomer subunit of the COPI complex that 
coats vesicles during protein transport, cause a craniofacial syndrome and developmental 
delay (ARCN1-related syndrome).168 DHX9 (DExH-Box-Helicase 9) in the NCF2 locus in 
1q25.3 was upregulated in females but downregulated in male B cells. It has a range of 
important functions as a nucleic acid helicase, and its role in autoimmune processes could 
potentially be numerous. DHX9 has been shown to bind specifically to inverted-repeat Alu 
elements and inhibits the amount of circular-RNAs in cells169 to limit transposon activity in 
the genome, but transcription of Alu elements and their binding to Ro60 - the target of anti-
Ro60 autoantibodies - is part of a feedback loop of type I interferon responses and initiation, 
a key process in systemic autoimmunity.170 While neither of these sex-eQTLs replicated in 
the GTEx tissue data, both could have implications in sex-specific autoimmune disease by 
affecting specific processes not measurable in whole tissue samples. These, as well as all the 
sex-eQTLs discovered, are worthy of further study particularly in a disease setting. 
In summary, we set out to discover sex-eQTL effects for variant-gene pairs in a set of 
21 genetic loci independently associated with systemic autoimmune disease. In our published 
study, we discovered 7 interactions in 6 independent loci, and found 5 more variant-gene 
pairs, 3 of them in loci without sex-eQTLs in the first study, in the public GTEx sex-
influenced eQTL analysis data. This would indicate that half of the loci associated with 
female predominant systemic autoimmune diseases have potential sex-eQTL effects, with 
important implications for the pathogenicity of these variants and the susceptibility and 
disease progression of these diseases.  
4.1.3 The novel disordered in autoimmunity (DIORA) gene family  
Before the publication of the first genome-wide association study for Sjögren’s syndrome, the 
association of genetic variants in the FAM167A-BLK locus on 8p23.1 with disease risk had 
already been published.45 This association was later confirmed in a genome-wide study43 and 







Figure 4: GWAS catalog entries for the chr8p23.1 locus  
(accessed via the UCSC Table browser.171 
The associated variants are spread over the intergenic region between FAM167A and 
BLK (Paper III, Figure 1). FAM167A stands for Family with sequence similarity 167, 
member A, while BLK stands for B lymphoid kinase and both are situated in an approximately 
4.5 Mb long region on chromosome 8 that has been inverted in a large portion of the human 
population, constituting the largest polymorphic inversion in our genome, the 8p23 inversion 
polymorphism.172 The autoimmune associations are more often found on the non-inverted 
genotype, suggesting that the inversion itself is protective.173  
The associated signal stretches closer to BLK, and the known role for BLK in B cell 
function would suggest any causal effect of this genetic association to be due to effects on 
BLK, but at a closer look at the eQTL effects of these variants on nearby genes diverted 
attention to FAM167A. We analyzed human B cells for eQTL effects of the associated 
variants (rs13277113), and found FAM167A expression to be profoundly different between 
genotypes, with the levels in risk allele carriers being almost double that in non-risk carriers, 
while the eQTL effect on BLK expression was significant but modest towards a reduction in 
risk allele carriers. A study published later found that the eQTL effects for these variants on 
FAM167A were among the most prominent in the human genome,62 with a P value of 
2.48*10-80 for the eQTL effect of rs4840658 on FAM167A expression in B cells. They also 
found significant eQTL effects on BLK in both B and T cells.  
We found FAM167A to be highly expressed in mouse lung tissues, followed by spleen 
and muscle, and specifically in B cells. More recently, fine mapping of eQTL effects on a 
larger scale have become available through GTEx,174 where one can see that although the 
gene is highly expressed in lung, surprisingly, the expression there does not appear to be 
affected by the polymorphisms to the same extent as in the immune cells (Figure 5). In the 
GTEx data the eQTL significance peak is visible for the whole region between the two genes 




Figure 5: GTEx IGV Browser overlay for the associated signals on chromosome 8  
(www.gtexportal.org accessed on 2020-10-29). 
We later found FAM167A to be expressed in both B cells and plasma cells in salivary 
gland infiltrates from patients with Sjögren’s syndrome, where it correlated positively with 
disease markers such as serum IgG levels, anti-Ro/La autoantibodies and salivary gland focus 
score,175 further solidifying its implication in disease pathogenesis.  
Aside from the prominent eQTL effect and proximity to disease associated alleles, the 
function of FAM167A was unknown. The sequence had only one gene with any sequence 
homology, so the pair were grouped into the family with sequence similarity 167, members A 
and B. Both genes lacked known motifs or domains, outside the “DUF3259” that grouped 
them together, but they were both highly preserved, with homologues even in invertebrates. 
The structure of both proteins is unknown, but they both have signs of a high degree of 
predicted disorder. Intrinsically disordered proteins have widespread roles in biological 
processes but do not fold into stable protein structures and instead flow and fold in a context 
dependent manner. This gives a level of flexibility impossible for rigid three dimensional 
structures seen in non-disordered proteins (reviewed in: 176), and the importance of 
intrinsically disordered proteins in immune function is constantly becoming more evident.177 
Given the importance of FAM167A in autoimmune susceptibility, and its apparent 
structural disorder, we named the gene family disordered autoimmunity (DIORA) and the two 
family members 1 and 2. While our data suggests an important role for DIORA1 in both the 
susceptibility and potentially even the pathogenesis of many autoimmune diseases, this does 
not disprove any association with BLK. Knocking out Blk in mice has only a mild B cell 
phenotype,178 but Src family proteins such as BLK are important regulators of B cell function 
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in both health and autoimmunity (reviewed in: 179), and more studies will be needed before 
we can fully understand the interplay between genetics and protein function in systemic 
autoimmune pathogenesis.  
4.2 AUTOIMMUNE CONGENITAL HEART BLOCK  
Autoimmune congenital heart block is an acquired, permanent heart condition that occurs 
during gestational week 18-24 of pregnancy in a small percentage of fetuses exposed to 
maternal anti-Ro/La autoantibodies in utero. Diagnosis is usually made in utero, or more 
rarely after birth. The incidence of congenital heart block is 1-4% in autoantibody exposed 
pregnancies, but increases to 12-16% if the mother has previously had an affected child. The 
higher recurrence rate compared to the incidence numbers when considering all anti-Ro/La 
positive pregnancies suggests some qualitative difference in the autoantibodies or maternal 
factors aside from the persistent maternal autoantibodies might increase the risk of congenital 
heart block. However, the recurrence is still low, so fetal susceptibility factors are also likely 
to be of importance. Fetal genetic factors are a logical source of risk. However, the maternal 
autoimmunity per se is associated with genetic profiles deviating from the normal population, 
which complicates the genetic analysis. Autoimmune risk genes will often be inherited from 
mother to offspring according to normal Mendelian laws and may thus cause higher 
frequencies of such alleles compared to healthy controls - and discerning true genetic 
associations with congenital heart block from inherited genetic autoimmune risk factors 
becomes difficult,180 regardless of any role these autoimmune associated genetic variants 
might play in congenital heart block pathogenesis. 
4.2.1 Genetic associations with autoimmune congenital heart block 
Autoimmune congenital heart block is a rare disease, affecting 1:23,000 births in Sweden.141 
The rarity makes it difficult to collect enough cases for genetic analysis, so in addition to 
collecting as many cases as possible in Sweden we expanded our search and collaborated to 
collect congenital heart block cases from five European countries; Sweden, Norway, Finland, 
Greece and Italy, and compared them with healthy controls in a genome-wide association 
study.  
Using a mixed linear model association test with a genetic relationship matrix to 
account for relatability, we compared 213 congenital heart block cases with 5671 population 
controls, analyzing 559,075 genetic variants. Two independent loci passed the Bonferroni-
corrected significance cutoff of p<8.9*10-8 (paper IV, figure 1), one in the HLA locus on 
chromosome 6, at p=8.08*10-9, and another on chromosome 1, near KCNT2, at p=7.4*10-8. 
Previous studies have described associations with variants in the HLA locus and cardiac 
neonatal lupus (including any cardiac phenotype for neonatal lupus, not only complete heart 
block cases130) and complete congenital heart block,131-133 however, we found that the signal 
we discovered as associated with CHB (with the best association represented by rs6906021) 
was independent from the previously described signal (rs3099844, R2 0.12). To understand if 
we might have a second independent signal in the HLA region, we performed a conditional 
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analysis, conditioning on rs6906021. The top variant in the conditional analysis was 
rs1150755, and that signal was in higher linkage disequilibrium with the previously reported 
variant (R2 0.57), but the association with that signal did not reach significance after 
conditioning on the top HLA variant (pcond=4.1*10
-5) but was suggestively associated in the 
original association test (p= 5.1*10-7). Given the previous association, one might speculate 
that with a larger cohort, both signals might pass the significance cutoff, however, we could 
not replicate this signal in the current study.  
Few genome-wide association studies with congenital heart block have been 
published. However, the association between neonatal lupus and/or congenital heart block 
susceptibility and HLA types has been known for a long time.131,133,181 Therefore, we wanted 
to understand if the signals we discovered in the HLA region were tagging particular HLA 
types, and used a dataset of genotyped and HLA typed Swedish controls to calculate 
associations between our alleles and HLA types (paper IV, figure 2C). We could not find our 
top signal (rs6906021) to tag a particular HLA type in our analysis. However, the previously 
described associated polymorphism130 (rs3099844), and to a lesser extent our second, less 
associated, signal (rs1150755) correlated well with HLA-B*08:01 and to some extent with 
HLA-DRB1*03. These two alleles are part of a haplotype associated with SLE and Sjögren's 
syndrome, and the signal may thus rather represent the maternal autoimmunity genetics. 
Whether our top HLA SNP represents a true CHB-associated signal is difficult to prove; 
while it does not tag any SLE or SS-related HLA it is noteworthy that no signals with such 
low p-values have been observed in CHB family investigations of the HLA region using 
transmission disequilibrium test (TDT) based analysis.131-133 
The second significant signal we discovered was near KCNT2 on chromosome 1. 
Potassium Sodium-Activated Channel Subfamily T member 2, or KCNT has also been named 
SLICK and SLO2.1, and encodes a potassium channel activated by intracellular sodium and 
chloride levels expressed in a number of cell types, including cardiomyocytes where it 
functions in mitochondria.182 The locus, chr 1q31.1 has a number of interesting features in the 
context of congenital heart block risk. First, previous genome-wide association studies have 
identified suggestively associated variants in the region,130 although, we could not find high 
linkage disequilibrium between our best association (rs12567147) and the previously 
described association (rs1890645). Second, the variants are located in an intergenic region 
downstream of KCNT2, but further downstream of these variants lies Ro60, the gene 
encoding the Ro60 protein to which the anti-Ro autoantibodies binds. We could however not 
identify any functional connection between the variants and expression of Ro60, but the 
proximity is interesting.  
The third point of interest for the chr1q31.1 locus is the proximity to the complement 
factor-H genes further upstream of KCNT2. Using the GTEx database,174 we identified 
associated variants that had eQTL effects on one of the factor-H genes, CFHR3 (paper IV, 
supplementary figure 2A), but the HLA variants associated with congenital heart block also 
had eQTL effects on C4A expression in the heart, suggesting a broad complement 
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dysregulation in individuals carrying the congenital heart block risk alleles. Variants in the 
factor-H genetic region, independent of the associated signal we discovered, have been 
associated with systemic lupus erythematosus susceptibility,183 younger age at lupus nephritis 
onset,184 and serum complement (C3 and C4) levels.185 The systemic lupus erythematosus 
susceptibility variant described by Zhao et al. (rs6677604183), has a similar eQTL effect on 
factor-H genes, including CFHR3,174 so overlapping pathways could hypothetically be at play 
in both diseases. Overall, there are multiple potential causes for congenital heart block 
susceptibility in the 1p31.1 locus, and functional effects of variation in this locus warrants 
further study.  
Systemic interferon activation is a hallmark of systemic autoimmune diseases such as 
Sjögren’s syndrome and systemic lupus erythematosus, and interferon activity has also been 
implicated in congenital heart block. This will be discussed in detail in the following chapter 
on papers V and VI. Given the suggested role for interferon activation in the pathogenesis of 
congenital heart block, and the fact that fetal exposure to maternal anti-Ro/La autoantibodies 
is concomitant with increased interferon activity in affected neonates (discussed in papers V 
and VI), we examined genes near (+/-1 Mb) the associated variants in the HLA and KCNT2 
loci, as well as suggestively associated genes (p<1*10-5) for signs of interferon regulation in 
fetal cardiomyocytes. We treated cultured primary human fetal cardiomyocytes obtained 
from elective termination of normal pregnancies with either interferon alpha, interferon beta 
or control for six hours before measuring gene expression via microarrays. We found three 
dominating interferon responsive genes in the HLA locus, TAP1, TAP2, and TAPBP, as well 
as several others including C2 and complement factor-B (paper IV, figure 3B). In the KCNT2 
locus, all three nearby genes were IFN-regulated - KCNT2 was significantly upregulated after 
interferon-alpha treatment, miR4735 and CFH were both significantly upregulated only after 
interferon beta treatment. We then wanted to replicate this finding in whole human tissue, so 
we downloaded microarray data for atrial cardiac tissue, with or without atrial fibrillation 
(GDS accession number: GDS1559) and calculated interferon scores using two available 
genes (UBE2E2 and STAT1), with tissue from healthy hearts as a control, and compared the 
interferon score to KCNT2 and CFH expression levels. The array used did not have available 
probes for miR4735. Both analyzed genes were found to correlate with the interferon score 
also here, corroborating our observation that interferon influences genes near variants 
associated with congenital heart block. The same was true for genes near the suggestively 
associated loci, and there was a significant enrichment of interferon responsive genes among 
all the genes near loci associated below the suggestive p value (p<1*10-5) cutoff (paper IV, 
figure 3G).  
The associated variants in chromosome 1 are downstream of KCNT2, and thus 
deciphering the influence of the variants on upstream gene expression was not 
straightforward. To further elucidate this, we accessed publically available promoter capture 
Hi-C data via CHiCP186 and found signs of interactions between the associated region and the 
transcription start sites of KCNT2 and CFH particularly in macrophages suggesting some 
influence in immune cells. We looked for differential expression of genes near associated or 
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suggestively associated loci between peripheral blood mononuclear cells collected from the 
umbilical cords of neonates born to healthy mothers, and neonates born to mothers carrying 
anti-Ro/La autoantibodies (without congenital heart block), and found several differentially 
expressed genes in both the HLA signal and suggestively associated regions, although neither 
CFH nor KCNT2 were affected in these cells.  
In summary, we discovered two loci significantly associated with congenital heart 
block susceptibility, in the HLA and KCNT2 regions on chromosomes 6 and 1, respectively. 
Variants in both of these loci influence the expression of complement genes, and the 
complement factor-H encoding gene is in the associated locus on chromosome 1. Interferon 
responsive genes were enriched among the genes near both of the significantly associated 
loci, and many suggestively associated ones, indicating a potential role for the interplay 
between interferon activity and fetal genetic factors in congenital heart block pathogenesis.  
4.2.2 Interferon activation in newborns exposed to anti-Ro/La 
autoantibodies  
Patients with systemic autoimmune diseases, including Sjögren’s syndrome, often have 
measurable interferon in their circulation. Systemic activation of interferon-induced genes is 
thus a hallmark of these diseases, often used as a proxy for type I interferon activity due to 
issues with direct measurements of type I interferons as previously discussed. Type II 
interferon, represented by the single protein interferon-, can be more readily measured 
directly. The presence of type I and type II interferons have been reported to precede the 
diagnosis of systemic lupus erythematosus, with type II interferons appearing before 
autoantibody positivity, and upregulation of type I interferon responsive genes coinciding 
with the induction of clinically detectable disease in that report.187 Upregulation of type I 
interferon responses before autoantibody appearance and disease onset has however been 
found in the context of e.g. type 1 diabetes, and it is not unlikely it may occur also in systemic 
autoimmunity. Interferons are known to be induced by a number of pathways with potential 
relevance for autoimmune pathogenesis (reviewed in: 188), including induction by anti-
ribonucleoprotein autoantibodies such as anti-DNA/histone and anti-Ro/La antibodies, 
although the concomitant presence of priming type I interferon appears necessary.189 
The risk of developing congenital heart block is closely linked to the presence of 
maternal anti-Ro/La autoantibodies. The autoantibodies of IgG class are, as other IgGs, 
transported across the placenta to the fetus where they have been suggested to contribute to 
development of the complete atrioventricular (AV) block, although the mechanism remains to 
be defined. Cross-reactivity with cell-surface expressed targets have been reported, but no 
unanimous target has been described or reconfirmed (reviewed in: 190). At the time when we 
initiated this study, no one had considered that the autoantibodies may actually also 
contribute to spark interferon production in the baby, or that the baby expected by a mother 
with high interferon activation may also have high expression of interferon-regulated genes. 
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4.2.2.1 Interferon production in Ro/La-exposed neonates 
We hypothesized that the same mechanism, involving anti-Ro/La autoantibodies, may be 
inducing interferon in both the mothers and the baby in utero. To test this, and understand if 
neonatal cells can produce interferon upon autoantibody-exposure, we set up experiments 
where cells from both control and antibody exposed neonates were cultured in the presence of 
plasma from neonates of anti-Ro/La positive mothers or healthy control neonates. Both 
groups released high amounts of interferon-alpha when exposed to the autoantibody 
containing plasma, but neither the cells from autoantibody-exposed neonates, nor the healthy 
control cells responded to the control serum (paper V, figure 4). Cells and plasma from 
autoantibody positive mothers were used as a positive control as this setup is known to yield 
interferon production.189 The fact that neonatal cells can produce interferons in response to 
autoantibodies does not mean they do so in vivo, and to investigate fetal production of 
interferon we measured interferon levels in blood and performed flow cytometry with 
intracellular staining of interferon-. Indeed, both type I and type II interferon were detectable 
in plasma of neonates exposed to Ro/La autoantibodies in utero, and both their T cells and 
NK cells were found to express interferon-, even without ex vivo re-stimulation (paper VI, 
figure 5).  
These data demonstrate that neonatal cells can produce interferon in response to 
autoantibody-containing fetal plasma, and that interferon is indeed produced in the fetus 
when exposed to Ro/La autoantibodies, although this was only evaluated for interferon-. In 
PBMCs, interferon- is predominantly produced by plasmacytoid dendritic cells. This cell 
population is present in low frequencies, and establishing flow cytometry, including 
evaluating antibodies for flow cytometric application for interferon-, is a current project in 
the research group. Interferon in the neonate could potentially also originate from the mother, 
directly passing through the placenta. Our observations do not exclude this possibility, and 
while it appears likely at least some of the maternal interferon can reach the fetus, direct 
evidence of mid-gestational transplacental interferon transfer is still lacking. Notably though, 
these two sources of interferon are not mutually exclusive, and even low levels of transfer of 
interferon from the mother may provide the fetal cells with the priming necessary at least in 
vitro for autoantibody-mediated interferon production by immune cells.189 
4.2.2.2 Downstream effects of fetal interferon 
To understand downstream effects of the interferon activation, and if interferon-regulated 
genes are affected in neonates exposed to anti-Ro/La autoantibodies in utero, we collected 
samples of blood from anti-Ro/La positive women and their neonates at the time of birth, as 
well as healthy control pairs, and analyzed the samples for gene expression and cellular 
populations (Papers V and VI). The clinical features of the individuals included in each study 
are listed in paper V, table 1 and paper VI, table 1.  
As expected, the anti-Ro/La autoantibody positive mothers had notable differences in 
gene expression of PBMCs, with 1795 genes being differentially regulated, both up and 
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down, between the two groups (paper V, figure 1). This effect was evident regardless of the 
maternal diagnosis, and rather related to the presence of the autoantibodies. As previously 
described,191 the mothers also had relative T cell lymphopenia and differences in the 
frequencies of B cell subsets, with lower frequencies of naïve B cells and higher frequencies 
of memory and marginal-zone B cells (paper VI, figure 1).  
The neonates did not differ in B and T cell frequencies between groups, however, the 
neonates exposed to maternal autoantibodies had higher frequencies of CD56dimCD16high NK 
cells (paper VI, figure 2). Despite only select populations differing in frequencies, there was 
an even greater gene dysregulation between the neonates born to healthy control mothers 
compared to the neonates exposed to maternal autoantibodies in utero, with a majority of the 
differentially expressed genes being upregulated in the autoantibody exposed group (paper V, 
figure 1). Some of the differentially regulated genes were shared between the maternal and 
neonatal analysis, but both comparisons also had unique genes that differed between groups, 
so the difference observed in the neonates was not a mere mirror image of the maternal 
effects. Gene ontology (GO) analysis also showed different pathways being enriched in the 
maternal versus neonatal analysis. The differentially expressed genes in the neonates included 
genes belonging to interferon, immune response pathways and others, but less specific 
pathways such as vesicle coating and platelet derived growth factor signaling were enriched 
in the mother. The pathways shared between mothers and neonates on the other hand, were 
all virus response and interferon pathways, with the viral pathways presumably identified 
because of the overlap with interferon signaling (paper V, figure 1B). PBMCs from the 
neonates exposed to maternal autoantibodies also displayed upregulation of NK cell related 
genes (paper VI, figure 3). None of the neonates included were diagnosed with congenital 
heart block, and yet, their cells were upregulating interferon response genes to the same 
extent as cells from their mothers.  
To further understand the extent of this interferon activation in both groups, we 
specifically examined GO terms related to the regulation of type I interferon production, and 
the responses to type I interferon. There we observed signs of interferon response genes being 
upregulated in autoantibody exposed mothers and neonates, suggesting that PBMCs from 
both groups had been exposed to type I interferons. Interestingly, cells from both mothers and 
neonates were also upregulating genes involved in the regulation of type I interferon 
production, alluding to the local production of interferons in the neonates. We next calculated 
an interferon score for all the samples and found significant increases in the interferon score 
of both mothers and neonates exposed to autoantibodies. In this context we also looked at 
mother-neonate pairs that had previously been excluded due to maternal immunomodulatory 
treatment. Contrary to what others have described,192 we could see no significant difference 
in the interferon scores of mothers receiving hydroxychloroquine compared to the untreated 
mothers. Although the group was small, all but one mother from the treated group had 
interferon scores comparable to the untreated mothers. It is however possible that their 
interferon score before treatment was higher. The neonates of treated mothers on the other 
hand had significantly lower interferon scores. When comparing the interferon scores of 
 
32 
mothers and neonates, we could see a clear correlation between maternal and neonatal 
interferon scores in untreated pairs (r2 0.87). The treated pairs did not have this correlation, 
suggesting that the hypothesis that interferons would cross the placenta specifically in 
autoimmune affected pregnancies,193 but not healthy pregnancies,194 might not explain the 
interferon found in the neonates, or perhaps that the immunomodulatory treatment prevents 
that.  
Notably, neonates of mothers with hydroxychloroquine treatment also had reduced 
frequencies of NK cells compared to neonates born to untreated mothers, suggesting a 
protective effect of maternal immunomodulatory treatment on interferon activation in the 
neonates. Protective effects of immunomodulatory treatment in CHB have been suggested 
based on clinical experience,125,195 and a first open label trial,126 although this remains to be 
fully proven.  
In addition to the type I interferon activation, type II interferon and fetal NK cell 
activation could provide the link to more targeted tissue destruction in congenital heart block 
pathogenesis. Fetal NK cells have been suggested as robust inducers of tissue damage based 
on findings from neonatal autoimmune ovarian disease models (reviewed in 196). We found 
that neonates exposed to maternal anti-Ro/La autoantibodies had increased frequencies of NK 
cells, and that those NK cells had elevated intracellular interferon-gamma (paper VI, figure 
5). As previously mentioned, genetic association studies have pinpointed genetic variants in 
HLA-C as associated with congenital heart block.131,133 Interestingly, the identified allele 
(Cw*06), has a protective effect. This allele distinguishes itself by being lowly expressed, 
and has a more restricted peptide binding than other HLA-Cs, suggesting that higher HLA-C 
expression and perhaps peptide presentation capacity increases the risk of CHB. The levels of 
HLA-C have been shown to influence NK cell subset frequencies,197 and we found that type I 
IFN stimulation of fetal cardiomyocytes upregulated HLA-C expression (paper VI, figure 4), 
suggesting a potential mechanism for the interplay of fetal genetic susceptibility, interferon 
activation and NK cells in congenital heart block pathogenesis.  
In our studies, we only had access to biologic material in terms of cord blood from term 
neonates. Interestingly however, fetal cardiac tissues from terminated pregnancies in which 
the fetus developed CHB display interferon activity,139 demonstrating that the interferon 
activation also takes place in the affected organ. This interferon has been suggested to cause 
injury in the affected hearts by damaging fetal fibroblasts,138 in a macrophage dependent 
manner,137 where upregulation of the activation marker SIGLEC1 in affected fetal hearts and 
on maternal cells,136 was suggested as a marker of interferon activation and high risk. We 
found upregulation of SIGLEC1 on monocytes from anti-Ro/La positive mothers as well as 
their neonates (paper V, figure 3). While our findings show that anti-Ro/La autoantibody 
containing plasma can induce type I interferons from fetal cells, with potential implications 
for interferon activation in exposed fetal tissues, it also suggests that the interferons - just like 
the anti-Ro/La autoantibodies - are necessary but might not be sufficient to induce congenital 
heart block without the presence of additional pathological factors.  
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In summary, we found that neonates exposed to maternal anti-Ro/La autoantibodies have 
higher frequencies of NK cells, increased levels of interferon-alpha, intracellular interferon-
gamma, and differential expression of IFN-regulated genes at birth, compared to neonates 
born to healthy control mothers. We also found that this increase in interferon-activity is 
reduced when the mothers receive immunomodulatory treatment. We also showed for the 
first time that neonatal PBMCs respond to anti-Ro/La containing plasma by releasing type I 
interferons. Our findings add to the understanding of to what extent interferon activation 
happens in autoantibody exposed neonates, what effects immunomodulatory treatment might 
have on that interferon activation, and lastly, potential fetal sources of interferon production 





5 SUMMARY AND FUTURE PERSPECTIVES 
The work included in this thesis was focused on genetic variation associated with increased 
risk of systemic autoimmune diseases, primarily Sjögren’s syndrome, as well as one of its 
more severe comorbidities, congenital heart block.  
We examined the influence of genetic variants on particular disease sub-phenotypes, 
identifying distinct groups of Sjögren’s syndrome patients and the genetic and clinical 
variables that identify them. We found that Sjögren’s syndrome patients who do not carry the 
typical anti-Ro or anti-La autoantibodies have a disease more restricted to the affected glands, 
with fewer extraglandular manifestations, and none of the typical genetic variants associated 
with systemic autoimmune disease. Patients with Ro/La autoantibodies on the other hand, 
have significant associations with variants in the HLA region that vary between different 
clinical manifestations. Our conclusion is that stratifying patients by these autoantibodies will 
be important for prognostic estimations and in follow-up, as well as in clinical trials and for 
choosing treatment. While patients belonging to the autoantibody-positive group are more 
likely to suffer severe disease manifestations, further study of the autoantibody-negative 
group might reveal pathogenic mechanisms specific for the glandular inflammation and tissue 
destruction observed in these patients. 
To elucidate why there is such a prominent sexual dimorphism in systemic 
autoimmune diseases such as Sjögren’s syndrome, we identified disease associated genetic 
variants with a sex-specific impact on gene expression in cells important for disease 
pathogenesis. Further understanding the difference between males and females in this context 
will clarify important pathways of disease pathogenesis and potentially reveal new ways to 
treat or manage systemic autoimmunity.  
Furthermore, we specifically examined an unknown gene affected by genetic variants 
associated with autoimmune susceptibility, FAM167A/DIORA-1 and its gene family, and 
found important implications for this gene in disease biology. The DIORA family of 
disordered proteins should be further characterized, and the mechanism behind the profound 
effect disease associated variants have on DIORA-1 expression warrants further study.  
 Additionally, we identified novel genetic associations with autoimmune congenital 
heart block in a case-control association study. These variants should be studied further in the 
context of the interplay between maternal autoimmunity and fetal disease susceptibility. 
Genes near the associated variants showed clear signs of interferon influence in their 
regulation, suggesting an interplay between interferon activation and genetics in congenital 
heart block susceptibility. We further characterized the interferon activation in autoantibody-
exposed pregnancies and found distinct signs of interferon activity in exposed neonates as 
well as an overall immune activation. Our findings suggest a hypothesis where autoantibodies 
and interferons may initiate pathways of tissue destruction that are dampened in most 
individuals but escalate in carriers of genetic susceptibility factors into irreversible tissue 
damage and loss of conduction through the atrioventricular node. Further studies will be 
needed to support this hypothesis and hopefully pinpoint particular risk factors that can be 
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